| First Author | Sánchez-Blázquez P | Year | 2020 |
| Journal | Mol Brain | Volume | 13 |
| Issue | 1 | Pages | 150 |
| PubMed ID | 33176836 | Mgi Jnum | J:298984 |
| Mgi Id | MGI:6489646 | Doi | 10.1186/s13041-020-00676-4 |
| Citation | Sanchez-Blazquez P, et al. (2020) The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception. Mol Brain 13(1):150 |
| abstractText | The Sigma-1 receptor (sigma1R) has emerged as an interesting pharmacological target because it inhibits analgesia mediated by mu-opioid receptors (MOR), and also facilitates the development of neuropathic pain. Based on these findings, the recent cloning of the Sigma-2 receptor (sigma2R) led us to investigate its potential role as a regulator of opioid analgesia and of pain hypersensitivity in sigma2R knockout mice. In contrast to sigma1R deficient mice, sigma2R knockout mice developed mechanical allodynia following establishment of chronic constriction injury-induced neuropathic pain, which was alleviated by the sigma1R antagonist S1RA. The analgesic effects of morphine, [D-Ala, N-MePhe, Gly-ol]-encephalin (DAMGO) and beta-endorphin increased in sigma1R(-/-) mice and diminished in sigma2R(-/-) mice. The analgesic effect of morphine was increased in sigma2R(-/-) mice by treatment with S1RA. However, sigma2R(-/-) mice and wild-type mice exhibited comparable antinociceptive responses to the delta receptor agonist [D-Pen2,5]-encephalin (DPDPE), the cannabinoid type 1 receptor agonist WIN55,212-2 and the alpha2-adrenergic receptor agonist clonidine. Therefore, while sigmaR1 inhibits and sigma2R facilitates MOR-mediated analgesia these receptors exchange their roles when regulating neuropathic pain perception. Our study may help identify new pharmacological targets for diminishing pain perception and improving opioid detoxification therapies. |
